Clinicopathologic and Genomic Characterization of PD‐L1 Positive Urothelial Carcinomas

INTRODUCTION: Pembrolizumab was approved with an accompanying companion diagnostic (CDx) assay (PD‐L1 DAKO 22C3) for urothelial carcinoma (UC). In this study, we further characterize the clinicopathologic and genomic features of UC that are programmed death‐ligand 1 (PD‐L1) positive. MATERIALS AND M...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Huang, Richard S.P., Haberberger, James, Harries, Lukas, Severson, Eric, Duncan, Daniel L., Ferguson, N. Lynn, Hemmerich, Amanda, Edgerly, Claire, Murugesan, Karthikeyan, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Hiemenz, Matthew, Venstrom, Jeffrey, Elvin, Julia A., Creeden, James, Lin, Douglas I., Ross, Jeffrey S., Ramkissoon, Shakti H.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2021
Matèries:
Cancer Diagnostics and Molecular Pathology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100538/
https://ncbi.nlm.nih.gov/pubmed/33687775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13753
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars